Taken together, the protective effects of Curc-mPEG454 against hepatic steatosis are possibly via specific inhibition of PPAR-γ/CD36 pathway activation and subsequent reduction of FFA uptake and TG synthesis in the liver. The gene discussed is CD36; the disease is Hepatic steatosis.